

Summary of the Advisory Board Virtual General Business Meeting

The Advisory Board Virtual General Business Meeting took place on Sunday, March 22nd.

Resolutions

The Advisory Board adopted the following resolutions:

- ***Coverage of Timely Treatment of Pediatric Vascular Anomalies; Laser Treatment of Port Wine Stains***
RESOLVED, the AAD/A should add to the Policy Statements support for the coverage of early intervention by laser treatment for pediatric patients with port wine stains.
- ***AAD/A Committee Policies***
RESOLVED, that the AAD BOD reconsider this policy and allow the membership to attend the committees with prior notification and that any committees not opened have a reason(s) for remaining closed transmitted to the full membership as well as the Advisory Board.
- ***American with Disabilities (ADA) Website Accessibility***
RESOLVED, that the Academy annually notify the membership of the requirement that practice websites must be ADA compliant by the most efficient means possible including the development of an AAD website toolkit that contains minimal standards that all dermatologists should take, to assist in the process.
- ***Industry Educational Programs***
RESOLVED, that in order to facilitate the highest level of information transfer, the AAD encourage industry to engage Doctors of Medicine or Doctors of Osteopathy when a clinician is utilized for an educational program.
- ***Cannabidiol (CBD) in Dermatology***
RESOLVED, the Board of Directors should create a CBD Ad Hoc Task Force to create and submit a report to the Board of Directors containing the details of its findings and recommendations.

Presentations

Academy Update, George Hruza, MD, AADA President

- Dr. Hruza discussed the Academy's response to COVID-19. Dr. Hruza formed the Ad Hoc Task Force on COVID-19 to address this urgent issue and track state, legislative, and regulatory developments.
- The AAD is working to develop resources that help with small businesses finances, aid in the adoption and coverage of telemedicine, information on how to comply with state laws and ongoing monitoring of CME requirements for the year.
- The AAD coronavirus webpage is continually updated:
<https://www.aad.org/member/practice/coronavirus>
- Additionally, Dr. Hruza discussed physician autonomy in medical decision-making and how it is up to dermatologists to decide what is considered essential care during this time of a national emergency.

Scope of Practice, Clifford Lober, MD

- Dr. Lober discussed the roles and different training requirements for PAs, NPs and dermatologists.
 - In Dr. Lober's presentation he showed the dramatic increase in the number of available Doctoral Nursing Programs over the past few years.

- Dr. Lober also spoke to truth in advertising issues where some medical titles can be misleading to the general public.
- He highlighted the importance of the AADA [position statement](#) that cites: “At certain times, and under the direction of a board-certified dermatologist, the practice of dermatology requires a team approach and may include other providers practicing in a dermatologic setting, including but not limited to: non-physician clinicians; allied health professionals; licensed personnel; and other personnel.”
- Dr. Lober’s recommendations included:
 - Encouraging continued education and training for all medical professionals.
 - Patients should have the right to see the medical care professional of their choice.
 - All practitioners should have name tags and signage so that patients know who is treating them.
 - Practitioners should introduce themselves by name and degree.

Drug Pricing/ PBMs, Mark Kaufmann, MD

- Dr. Kaufmann discussed the ongoing burden of rising drug prices for dermatologists and patients. He spoke to the increasing profits of PBMs and the need to eliminate rebates.
 - In Dr. Kaufmann’s presentation he discussed how the current Administration proposed to eliminate rebates, yet was not successful in finalizing the recommendation due to pushback from both the insurers and PBMs.
- He highlighted the work that AADA is doing to advocate on important pieces of legislation that have the potential to influence the drug supply chain and help with rising prices.
- Additionally, Dr. Lober spoke to the continued frustration with prior authorizations and step therapy processes that PBMs implement.

2021 Physician Payment Update, Melissa Piliang, MD

- Dr. Piliang discussed significant Medicare payment changes that will be implemented in 2021, including CMS’ proposals to change payment for codes 10- and 90-day global periods.
 - Dr. Piliang provided an overview of the history of AADA advocacy to preserve global periods. In 2017, the elimination of global periods was averted. In 2019, CMS dropped proposals to merge E/M reimbursements and instead accept CPT values developed by RUC.
- Dr. Piliang reported that CMS released its own estimates of the 2021 E/M changes on specialties and AADA staff extrapolated data from those estimates to determine the impact on different dermatology practices.
- Additionally, Dr. Piliang explained AADA’s multi-pronged global and E/M payment strategy. Members discussed communication channels to disseminate information on forthcoming payment changes.

Elections

The Advisory Board elected the following members:

- **Advisory Board Nominating Committee Member Representative:** George Elgart, MD, FAAD.
- **Executive Committee:** Holly Fritch, MD won a four-year term on the Executive Committee and Curtis Asbury, MD won a one-year term on the Executive Committee.

Summer Resolution Process

The call for summer resolutions will open on May 27th. The resolution deadline is June 24th.